Compare USNA & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | RCEL |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.1M | 403.3M |
| IPO Year | 1996 | 2018 |
| Metric | USNA | RCEL |
|---|---|---|
| Price | $13.39 | $16.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.26 |
| AVG Volume (30 Days) | 178.6K | ★ 429.2K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.20 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,060,902,000.00 | $71,610,000.00 |
| Revenue This Year | N/A | $24.33 |
| Revenue Next Year | $3.96 | $26.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $12.57 | $3.22 |
| 52 Week High | $23.59 | $16.90 |
| Indicator | USNA | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 37.78 | 67.16 |
| Support Level | $12.57 | $3.86 |
| Resistance Level | $15.58 | $16.90 |
| Average True Range (ATR) | 0.70 | 1.15 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 29.49 | 70.61 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.